Targeting RAS signalling pathways in cancer therapy (original) (raw)

• Barbacid, M. Ras genes. Annu. Rev. Biochem. 56, 779–827 (1987).
  Article CAS PubMed Google Scholar
• Bos, J. L. Ras oncogenes in human cancer: a review. Cancer Res. 49, 4682–4689 (1989).
  CAS PubMed Google Scholar
• Shields, J. M., Pruitt, K., McFall, A., Shaub, A. & Der, C. J. Understanding Ras: 'it ain't over 'til it's over'. Trends Cell Biol. 10, 147–154 (2000).
  Article CAS PubMed Google Scholar
• Campbell, S. L., Khosravi-Far, R., Rossman, K. L., Clark, G. J. & Der, C. J. Increasing complexity of Ras signaling. Oncogene 17, 1395–1413 (1998).
  Article CAS PubMed Google Scholar
• Wittinghofer, A. Signal transduction via Ras. Biol. Chem. 379, 933–937 (1998).
  CAS PubMed Google Scholar
• Lowy, D. R. & Willumsen, B. M. Function and regulation of ras. Annu. Rev. Biochem. 62, 851–891 (1993).
  Article CAS PubMed Google Scholar
• Johnson, L. et al. K-ras is an essential gene in the mouse with partial functional overlap with N-ras. Genes Dev. 11, 2468–2481 (1997).
  Article CAS PubMed PubMed Central Google Scholar
• Seabra, M. C. Membrane association and targeting of prenylated Ras-like GTPases. Cell Signal. 10, 167–172 (1998).
  Article CAS PubMed Google Scholar
• Cox, A. D. & Der, C. J. Farnesyltransferase inhibitors and cancer treatment: targeting simply Ras? Biochim. Biophys. Acta 1333, F51–F71 (1997).
  CAS PubMed Google Scholar
• Hancock, J. F., Magee, A. I., Childs, J. E. & Marshall, C. J. All ras proteins are polyisoprenylated but only some are palmitoylated. Cell 57, 1167–1177 (1989).
  Article CAS PubMed Google Scholar
• Hancock, J. F., Paterson, H. & Marshall, C. J. A polybasic domain or palmitoylation is required in addition to the CAAX motif to localize p21ras to the plasma membrane. Cell 63, 133–139 (1990). References 10 and 11 describe the original characterization of the modification of RAS by farnesylation and, in the case of HRAS and NRAS, but not KRAS, palmitoylation.
  Article CAS PubMed Google Scholar
• Reuther, G. W. & Der, C. J. The Ras branch of small GTPases: Ras family members don't fall far from the tree. Curr. Opin. Cell Biol. 12, 157–165 (2000).
  Article CAS PubMed Google Scholar
• Takai, Y., Sasaki, T. & Matozaki, T. Small GTP-binding proteins. Physiol. Rev. 81, 153–208 (2001).
  Article CAS PubMed Google Scholar
• Cullen, P. J. & Lockyer, P. J. Integration of calcium and Ras signalling. Nature Rev. Mol. Cell Biol. 3, 339–348 (2002).
  Article CAS Google Scholar
• Daub, H., Weiss, F. U., Wallasch, C. & Ullrich, A. Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors. Nature 379, 557–560 (1996).
  Article CAS PubMed Google Scholar
• Chiu, V. K. et al. Ras signalling on the endoplasmic reticulum and the Golgi. Nature Cell Biol. 4, 343–350 (2002).
  Article CAS PubMed Google Scholar
• Ebinu, J. O. et al. RasGRP, a Ras guanyl nucleotide-releasing protein with calcium- and diacylglycerol-binding motifs. Science 280, 1082–1086 (1998).
  Article CAS PubMed Google Scholar
• Downward, J., Graves, J. D., Warne, P. H., Rayter, S. & Cantrell, D. A. Stimulation of p21ras upon T-cell activation. Nature 346, 719–723 (1990).
  Article CAS PubMed Google Scholar
• Donovan, S., Shannon, K. M. & Bollag, G. GTPase activating proteins: critical regulators of intracellular signaling. Biochim. Biophys. Acta 1602, 23–45 (2002).
  CAS PubMed Google Scholar
• Leevers, S. J., Paterson, H. F. & Marshall, C. J. Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane. Nature 369, 411–414 (1994).
  Article CAS PubMed Google Scholar
• Marais, R., Light, Y., Paterson, H. F. & Marshall, C. J. Ras recruits Raf-1 to the plasma membrane for activation by tyrosine phosphorylation. EMBO J. 14, 3136–3145 (1995).
  Article CAS PubMed PubMed Central Google Scholar
• Yordy, J. S. & Muise-Helmericks, R. C. Signal transduction and the Ets family of transcription factors. Oncogene 19, 6503–6513 (2000).
  Article CAS PubMed Google Scholar
• Pruitt, K. & Der, C. J. Ras and Rho regulation of the cell cycle and oncogenesis. Cancer Lett. 171, 1–10 (2001).
  Article CAS PubMed Google Scholar
• Rodriguez-Viciana, P. et al. Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature 370, 527–532 (1994).
  Article CAS PubMed Google Scholar
• Pacold, M. E. et al. Crystal structure and functional analysis of Ras binding to its effector phosphoinositide 3-kinaseγ. Cell 103, 931–943 (2000). This describes the three-dimensional structure of RAS in complex with one of its effectors, PI3K. The size of the interaction interface shows the difficulty that is likely to face the design of inhibitors of protein–protein interaction.
  Article CAS PubMed Google Scholar
• Datta, S. R., Brunet, A. & Greenberg, M. E. Cellular survival: a play in three Akts. Genes Dev. 13, 2905–2927 (1999).
  Article CAS PubMed Google Scholar
• Khwaja, A., Rodriguez-Viciana, P., Wennstrom, S., Warne, P. H. & Downward, J. Matrix adhesion and Ras transformation both activate a phosphoinositide 3-OH kinase and protein kinase B/Akt cellular survival pathway. EMBO J. 16, 2783–2793 (1997).
  Article CAS PubMed PubMed Central Google Scholar
• Lambert, J. M. et al. Tiam1 mediates Ras activation of Rac by a PI(3)K-independent mechanism. Nature Cell Biol. 4, 621–625 (2002).
  Article CAS PubMed Google Scholar
• Malliri, A. et al. Mice deficient in the Rac activator Tiam1 are resistant to Ras-induced skin tumours. Nature 417, 867–871 (2002).
  Article CAS PubMed Google Scholar
• De Ruiter, N. D., Burgering, B. M. & Bos, J. L. Regulation of the Forkhead transcription factor AFX by Ral-dependent phosphorylation of threonines 447 and 451. Mol. Cell. Biol. 21, 8225–8235 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Kelley, G. G., Reks, S. E., Ondrako, J. M. & Smrcka, A. V. Phospholipase Cε: a novel Ras effector. EMBO J. 20, 743–754 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Weiss, B., Bollag, G. & Shannon, K. Hyperactive Ras as a therapeutic target in neurofibromatosis type 1. Am. J. Med. Genet. 89, 14–22 (1999).
  Article CAS PubMed Google Scholar
• Mendelsohn, J. & Baselga, J. The EGF receptor family as targets for cancer therapy. Oncogene 19, 6550–6565 (2000).
  Article CAS PubMed Google Scholar
• Kuan, C. T., Wikstrand, C. J. & Bigner, D. D. EGF mutant receptor vIII as a molecular target in cancer therapy. Endocr. Relat. Cancer 8, 83–96 (2001).
  Article CAS PubMed Google Scholar
• Bellacosa, A. et al. Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int. J. Cancer 64, 280–285 (1995).
  Article CAS PubMed Google Scholar
• Simpson, L. & Parsons, R. PTEN: life as a tumor suppressor. Exp. Cell Res. 264, 29–41 (2001).
  Article CAS PubMed Google Scholar
• Sebti, S. M. & Hamilton, A. D. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies. Oncogene 19, 6584–6593 (2000).
  Article CAS PubMed Google Scholar
• Cox, A. D. & Der, C. J. Farnesyltransferase inhibitors: promises and realities. Curr. Opin. Pharmacol. 2, 388–393 (2002).
  Article CAS PubMed Google Scholar
• Kohl, N. E. et al. Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nature Med. 1, 792–797 (1995). The study that launched massive interest in farnesyl-transferase inhibitors as tumour therapeutic drugs aimed at RAS. Unfortunately, the activity turned out to be selective for HRAS, an isoform that is only very rarely activated in human tumours.
  Article CAS PubMed Google Scholar
• Lobell, R. B. et al. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models. Cancer Res. 61, 8758–8768 (2001).
  CAS PubMed Google Scholar
• Prendergast, G. C. Actin' up: RhoB in cancer and apoptosis. Nature Rev. Cancer 1, 162–168 (2001).
  Article CAS Google Scholar
• Ohkanda, J., Knowles, D. B., Blaskovich, M. A., Sebti, S. M. & Hamilton, A. D. Inhibitors of protein farnesyltransferase as novel anticancer agents. Curr. Top. Med. Chem. 2, 303–323 (2002).
  Article CAS PubMed Google Scholar
• Singh, S. B. & Lingham, R. B. Current progress on farnesyl protein transferase inhibitors. Curr. Opin. Drug. Discov. Devel. 5, 225–244 (2002).
  CAS PubMed Google Scholar
• Cortes, J. E. et al. Efficacy of the farnesyl transferase inhibitor, ZARNESTRATM (R115777), in chronic myeloid leukemia and other other hematological malignancies. Blood 31, 31 Oct 31 2002 [epub ahead of print].
  Google Scholar
• Crooke, S. T. Potential roles of antisense technology in cancer chemotherapy. Oncogene 19, 6651–6659 (2000).
  Article CAS PubMed Google Scholar
• Mukhopadhyay, T., Tainsky, M., Cavender, A. C. & Roth, J. A. Specific inhibition of K-ras expression and tumorigenicity of lung cancer cells by antisense RNA. Cancer Res. 51, 1744–1748 (1991).
  CAS PubMed Google Scholar
• Chen, G., Oh, S., Monia, B. P. & Stacey, D. W. Antisense oligonucleotides demonstrate a dominant role of c-Ki-RAS proteins in regulating the proliferation of diploid human fibroblasts. J. Biol. Chem. 271, 28259–28265 (1996).
  Article CAS PubMed Google Scholar
• Monia, B. P., Johnston, J. F., Geiger, T., Muller, M. & Fabbro, D. Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase. Nature Med. 2, 668–675 (1996).
  Article CAS PubMed Google Scholar
• HŸser, M. et al. MEK kinase activity is not necessary for Raf-1 function. EMBO J. 20, 1940–1951 (2001).
  Article Google Scholar
• Coudert, B. et al. Phase II trial with ISIS 5132 in patients with small-cell (SCLC) and non-small cell (NSCLC) lung cancer. A European Organization for Research and Treatment of Cancer (EORTC) Early Clinical Studies Group report. Eur. J. Cancer 37, 2194–2198 (2001).
  Article CAS PubMed Google Scholar
• Sawyers, C. L. Rational therapeutic intervention in cancer: kinases as drug targets. Curr. Opin. Genet. Dev. 12, 111–115 (2002).
  Article CAS PubMed Google Scholar
• Hoshino, R. et al. Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 18, 813–822 (1999).
  Article CAS PubMed Google Scholar
• Dudley, D. T., Pang, L., Decker, S. J., Bridges, A. J. & Saltiel, A. R. A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc. Natl Acad. Sci. USA 92, 7686–7689 (1995).
  Article CAS PubMed PubMed Central Google Scholar
• Favata, M. F. et al. Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J. Biol. Chem. 273, 18623–18632 (1998).
  Article CAS PubMed Google Scholar
• Sebolt-Leopold, J. S. Development of anticancer drugs targeting the MAP kinase pathway. Oncogene 19, 6594–6599 (2000).
  Article CAS PubMed Google Scholar
• Sebolt-Leopold, J. S. et al. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nature Med. 5, 810–816 (1999).
  Article CAS PubMed Google Scholar
• Lyons, J. F., Wilhelm, S., Hibner, B. & Bollag, G. Discovery of a novel Raf kinase inhibitor. Endocr. Relat. Cancer. 8, 219–225 (2001).
  Article CAS PubMed Google Scholar
• Davies, H. et al. Mutations of the BRAF gene in human cancer. Nature 417, 949–954 (2002).
  Article CAS PubMed Google Scholar
• Normanno, N., Bianco, C., De Luca, A. & Salomon, D. S. The role of EGF-related peptides in tumor growth. Front. Biosci. 6, D685–D707 (2001).
  Article CAS PubMed Google Scholar
• Sibilia, M. et al. The EGF receptor provides an essential survival signal for SOS-dependent skin tumor development. Cell 102, 211–220 (2000). An elegant transgenic mouse study showing that the ability of activated endogenous RAS protein to promote tumour formation is dependent on the activity of EGFR, indicating the importance of autocrine EGF signalling in RAS transformation.
  Article CAS PubMed Google Scholar
• Fabbro, D., Parkinson, D. & Matter, A. Protein tyrosine kinase inhibitors: new treatment modalities? Curr. Opin. Pharmacol. 2, 374–381 (2002).
  Article CAS PubMed Google Scholar
• Wakeling, A. E. Epidermal growth factor receptor tyrosine kinase inhibitors. Curr. Opin. Pharmacol. 2, 382–387 (2002).
  Article CAS PubMed Google Scholar
• de Bono, J. S. & Rowinsky, E. K. The ErbB receptor family: a therapeutic target for cancer. Trends Mol. Med. 8, S19–S26 (2002).
  Article CAS PubMed Google Scholar
• Herbst, R. S. ZD1839: targeting the epidermal growth factor receptor in cancer therapy. Expert Opin. Investig. Drugs 11, 837–849 (2002).
  Article CAS PubMed Google Scholar
• Hidalgo, M. et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J. Clin. Oncol. 19, 3267–3279 (2001).
  Article CAS PubMed Google Scholar
• Schulze, A., Lehmann, K., Jefferies, H. B., McMahon, M. & Downward, J. Analysis of the transcriptional program induced by Raf in epithelial cells. Genes Dev. 15, 981–994 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Herbst, R. S. & Shin, D. M. Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer 94, 1593–1611 (2002).
  Article CAS PubMed Google Scholar
• Robert, F. et al. Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J. Clin. Oncol. 19, 3234–3243 (2001).
  Article CAS PubMed Google Scholar
• Slamon, D. J. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783–792 (2001). The results of the Phase III trials with trastuzumab (Herceptin) that showed it to be an effective treatment for metastatic breast cancer with amplification of ERBB2.
  Article CAS PubMed Google Scholar
• Xie, Y., Li, K. & Hung, M. C. Tyrosine phosphorylation of Shc proteins and formation of Shc/Grb2 complex correlate to the transformation of NIH3T3 cells mediated by the point-mutation activated neu. Oncogene 10, 2409–2413 (1995).
  CAS PubMed Google Scholar
• Keshamouni, V. G., Mattingly, R. R. & Reddy, K. B. Mechanism of 17-β-estradiol-induced Erk1/2 activation in breast cancer cells: A role for HER2 and PKC-δ. J. Biol. Chem. 277, 22558–22565 (2002).
  Article CAS PubMed Google Scholar
• Hunger, R. E. et al. Successful induction of immune responses against mutant ras in melanoma patients using intradermal injection of peptides and GM-CSF as adjuvant. Exp. Dermatol. 10, 161–167 (2001).
  Article CAS PubMed Google Scholar
• Reuveni, H. et al. Toward a PKB inhibitor: modification of a selective PKA inhibitor by rational design. Biochemistry 41, 10304–10314 (2002).
  Article CAS PubMed Google Scholar
• Bergo, M. O. et al. Absence of CAAX endoprotease Rce 1: effects on cell growth and transformation. Mol. Cell. Biol. 22, 171–181 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Kloog, Y., Cox, A. D. & Sinensky, M. Concepts in Ras-directed therapy. Exp. Opin. Investig. Drugs 8, 2121–2140 (1999).
  Article CAS Google Scholar
• Kimoto, M., Sakamoto, K., Shirouzu, M., Mirao, I. & Yokoyama, S. RNA aptamers that specifically bind to the Ras-binding domain of c-Raf-1. FEBS Lett. 441, 322–326 (1998).
  Article CAS PubMed Google Scholar
• Kato-Stankiewicz, J. et al. Inhibitors of Ras/Raf-1 interaction identified by two-hybrid screening revert Ras-dependent transformation phenotypes in human cancer cells. Proc. Natl Acad. Sci. USA 99, 14398–14403 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Ahmadian, M. R. et al. Guanosine triphopshatase stimulation of oncogenic Ras mutants. Proc. Natl Acad. Sci. USA 96, 7065–7070 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• Hidalgo, M. & Rowinsky, E. K. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene 19, 6680–6686 (2000).
  Article CAS PubMed Google Scholar
• Neckers, L. Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol. Med. 8, S55–S61 (2002).
  Article CAS PubMed Google Scholar
• Zucker, S., Cao, J. & Chen, W. T. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene 19, 6642–6650 (2000).
  Article CAS PubMed Google Scholar
• Rosen, L. S. Angiogenesis inhibition in solid tumors. Cancer J. 7 (Suppl. 3), S120–S128 (2001).
  PubMed Google Scholar
• Kirn, D., Niculescu-Duvaz, I., Hallden, G. & Springer, C. J. The emerging fields of suicide gene therapy and virotherapy. Trends Mol. Med. 8, S68–S73 (2002).
  Article CAS PubMed Google Scholar
• Biederer, C., Ries, S., Brandts, C. H. & McCormick, F. Replication-selective viruses for cancer therapy. J. Mol. Med. 80, 163–175 (2002).
  Article CAS PubMed Google Scholar
• Raff, M. C. Social controls on cell survival and cell death. Nature 356, 397–400 (1992).
  Article CAS PubMed Google Scholar
• End, D. W. et al. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res. 61, 131–137 (2001).
  CAS PubMed Google Scholar
• Rose, W. C. et al. Preclinical antitumor activity of BMS-214662, a highly apoptotic and novel farnesyltransferase inhibitor. Cancer Res. 61, 7507–7517 (2001). References 86 and 87 describe preclinical data on two of the leading farnesyltransferase inhibitors. The significant effects that are seen in these model systems are probably not due to targeting RAS, and it remains unclear whether they can be replicated in the clinic.
  CAS PubMed Google Scholar